Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease

HIGHLIGHTS

• who: Jayoung Lim and collaborators from the Department of Cardiology, Cardiovascular Center, Seoul National University Bundang Hospital have published the research work: Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease, in the Journal: PLOS ONE of May/19,/2022
• what: The authors aimed to compare the clinical outcomes between dapagliflozin empagliflozin and dipeptidyl peptidase-4 inhibitors (DPP4i) patients with type 2 diabetes without prior ASCVD CKD or HF. In the present study, the benefits for HF and renal outcomes did not . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.